Interesting facts
Interesting Facts about 1-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidyl]butan-1-one
This compound, often abbreviated as a novel pharmaceutical agent, has garnered significant interest in the field of medicinal chemistry due to its unique structural characteristics and potential therapeutic applications. Here are some intriguing facts:
- Complex Molecular Structure: The presence of both fluorine and trifluoromethyl groups within its molecular framework enhances the compound's lipophilicity, which can significantly influence its biological activities.
- Pharmacological Potential: Preliminary studies suggest that this compound may exhibit properties beneficial for treating mental health disorders, showcasing effectiveness in modulating neurotransmitter activity.
- Role of Piperidine: The inclusion of a piperidine moiety is crucial, as piperidines are well-known for their role in various drug formulations, primarily due to their ability to enhance pharmacological activity.
- Synthesis Challenges: The synthesis of this compound can be quite complex, often requiring specialized reagents and conditions to achieve the desired purity and yield, thus making it a topic of interest in synthetic organic chemistry.
- Research Implications: Ongoing research is aimed at exploring the full extent of its therapeutic potential, including its ability to tackle resistant strains of specific diseases.
In summary, 1-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidyl]butan-1-one represents a fascinating intersection of chemistry and pharmacology, highlighting how nuanced modifications in molecular structures can lead to significant advancements in treatment options. As a notable candidate for future drug development, its exploration continues to intrigue scientists and students alike.
Synonyms
Trifluperidol
749-13-3
Triperidol
Trisedil
Psychoperidol
Flumoperone
Psicoperidol
Trisedyl
Psicoperidol-R
McN-JR-2498
Trifluperidolo
R-2498
NSC 170978
P 459
1-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]butan-1-one
NSC-170978
CHEMBL15023
1-Butanone, 1-(4-fluorophenyl)-4-(4-hydroxy-4-(3-(trifluoromethyl)phenyl)-1-piperidinyl)-
R8869Q7R8I
NSC170978
4-Fluoro-4,4-idrossi-4-(m-trifluorometil-fenil)-piperidino-butirrofenone
Trifluperidolum
Trifluperidolo [DCIT]
Trifluperidolo [Italian]
1-(4-Fluorophenyl)-4-(4-hydroxy-4-(3-(trifluoromethyl)phenyl)piperidin-1-yl)butan-1-one
1-Butanone, 1-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-
Trifluperidolum [INN-Latin]
Butyrophenone, 4'-fluoro-4-(4-hydroxy-4-(.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)piperidino)-
Butyrophenone, 4'-fluoro-4-[4-hydroxy-4-(.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)piperidino]-
Trifluperidol [USAN:INN:BAN]
BRN 1556208
UNII-R8869Q7R8I
.psi.Coperidol
1-(4-fluorophenyl)-4-{4-hydroxy-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl}butan-1-one
.psi.Coperidol-R
4'-Fluoro-4-(4-hydroxy-4-(.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)piperidino)butyrophenone
4'-Fluoro-4-[4-hydroxy-4-(.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)piperidino]butyrophenone
Trifluperidol Free Base
Lopac-T-103
TRIFLUPERIDOL [MI]
TRIFLUPERIDOL [INN]
Trifluperidol (USAN/INN)
4'-Fluoro-4-(4-hydroxy-4-(alpha,alpha,alpha-trifluoro-m-tolyl)piperidino)butyrophenone
4-Fluoro-4,4-idrossi-4-(m-trifluorometil-fenil)-piperidino-butirrofenone [Italian]
TRIFLUPERIDOL [USAN]
Lopac0_001243
5-21-02-00406 (Beilstein Handbook Reference)
SCHEMBL120862
TRIFLUPERIDOL [MART.]
TRIFLUPERIDOL [WHO-DD]
DTXSID4023703
CHEBI:135662
HMS2090P16
BCP28492
BDBM50047016
CCG-205317
DB13552
SDCCGSBI-0051210.P002
Butyrophenone, 4'-fluoro-4-(4-hydroxy-4-(alpha,alpha,alpha-trifluoro-m-tolyl)piperidino)-
NCGC00015983-01
NCGC00015983-02
NCGC00015983-03
NCGC00015983-06
NCGC00162376-01
WLN: T6NTJ A3VR DF& DQ DR CXFFF
1ST161655
NS00010654
D02625
AB00918346-05
L001285
Q4463264
BRD-K43605761-003-05-4
R-2498; R 2498; R2498
Butyrophenone,.alpha.,.alpha.-trifluoro-m-tolyl)piperidino]-
1-(4-Fluoro-phenyl)-4-[4-hydroxy-4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-butan-1-one
1-(4-Fluorophenyl)-4-(4-hydroxy-4-(3-(trifluoromethyl)phenyl)-1-piperidinyl)-1-butanone
1-(4-Fluorophenyl)-4-(4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl)-1-butanone #
1-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidyl]-butan-1-one
1-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidyl]butan-1-one
4'-Fluoro-4-[4-hydroxy-4-(.alpha.,.alpha.-trifluoro-m-tolyl)piperidino]butyrophenone
1-(4-Fluoro-phenyl)-4-[4-hydroxy-4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-butan-1-one (trifluperidol)
1-Butanone, 1-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-pi peridinyl]-
Solubility of 1-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidyl]butan-1-one
The solubility of the compound C21H23ClFNO2, known for its intricate structure, can be influenced by various factors. Understanding its solubility is essential for applications in medicinal chemistry, formulation science, and beyond.
Solubility Characteristics
Given its complex molecular structure, this compound exhibits a range of solubility properties:
This compound's solubility profile is not just a simple matter of "soluble" or "insoluble." Instead, it requires a nuanced understanding of its interactions with various solvents. As the renowned chemist once said, "Solubility is the key to unlocking the potential of many compounds." Therefore, thorough experimentation is vital to determine the precise solubility features of this compound.